You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Acute Leukemias

  • Authors: Courtney D. DiNardo, MD, MSCE; Harry P. Erba, MD, PhD; Naval G. Daver, MD; Elias J. Jabbour, MD; Aaron C. Logan, MD, PhD; Jae H. Park, MD; Jessica Leonard, MD
  • CME / ABIM MOC / CE Released: 10/19/2022
  • Valid for credit through: 10/19/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.75 ABIM MOC points

    Nurses - 1.75 ANCC Contact Hour(s) (1.5 contact hours are in the area of pharmacology)

    Pharmacists - 1.75 Knowledge-based ACPE (0.175 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with hematologic disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), benign hematologic diseases, and other related conditions.

The goal of this activity is that learners will be better able to risk stratify and personalize treatment for patients with acute leukemias by integrating clinical trial data and evidence-based recommendations on novel therapies in the frontline and relapsed/refractory (R/R) settings.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Use of molecular analysis and risk stratification to guide therapy selection for patients with acute leukemias
    • Recent clinical trial data on treatment strategies for acute leukemias in the frontline and R/R settings
  • Have greater competence related to
    • Assessing measurable residual disease (MRD) in acute leukemias
    • Selecting evidence-based treatment for patients with acute leukemias in the frontline and R/R settings
  • Demonstrate greater confidence in their ability to
    • Personalize treatment for patients with acute leukemias in an interprofessional team-based environment


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Courtney D. DiNardo, MD, MSCE

    Associate Professor
    Department of Leukemia
    Division of Cancer Medicine
    University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Courtney D. DiNardo, MD, MSCE, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Agios/Servier; Astellas; Celgene/Bristol Myers Squibb; Cleave; Foghorn; Genentech; Gen Mab; Novartis; Notable Labs; Takeda
    Research funding from: AbbVie; Agios/Servier; Astex; Calithera; Celgene/Bristol Myers Squibb; Cleave; Foghorn; ImmuneOnc; Loxo

  • Harry P. Erba, MD, PhD

    Professor of Medicine
    Director, Leukemia Program
    Duke University
    Durham, North Carolina

    Disclosures

    Harry P. Erba, MD, PhD, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Astellas; Bristol Myers Squibb Company; Daiichi Sankyo; Genentech; Glycomimetics; Incyte; Jazz; Novartis; Servier
    Served as a speaker or a member of a speakers bureau for: AbbVie; Bristol Myers Squibb Company; Incyte; Jazz; Novartis; Servier

  • Naval G. Daver, MD

    Director
    Leukemia Research Alliance Program
    Associate Professor
    Department of Leukemia
    University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Naval G. Daver, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Agios; Arog; Astellas; Bristol Myers Squibb Company; Celgene; Daiichi Sankyo; Genentech; Gilead; Immunogen; Jazz; Novartis; Pfizer; Servier; Shattuck Labs; Syndax; Trillium
    Received grants for clinical research from: AbbVie; Amgen; Bristol Myers Squibb Company; Daiichi Sankyo; FATE Therapeutics; Genentech; Gilead; Glycomimetics; Hanmi; Immunogen; Novimmune; Pfizer; Servier; Trillium; Trovagene

  • Elias J. Jabbour, MD

    Professor
    Department of Leukemia
    Division of Cancer Medicine
    University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Elias J. Jabbour, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Amgen; Bristol Myers Squibb Company; Genentech; Novartis; Pfizer; Takeda
    Received grants for clinical research from: AbbVie; Amgen; Pfizer; Takeda

  • Aaron C. Logan, MD, PhD

    Associate Professor
    Hematology, Bone Marrow Transplantation, and Cellular Therapy
    University of California, San Francisco
    San Francisco, California

    Disclosures

    Aaron C. Logan, MD, PhD, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Bristol Myers Squibb Company; Pfizer
    Received grants for clinical research from: Amgen; Amphivena; Astellas; Autolus; Jazz; Kadmon; Kite; Pharmacyclics

  • Jae H. Park, MD

    Associate Professor
    Weill Cornell Medicine
    Director, Adult ALL Program
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Jae H. Park, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: Affyimmune; Allogene; Amgen; Artiva; Autolus; Bristol Myers Squibb Company; Curocel; Kite; Kura; Minerva; Novartis; Pepromene; Pfizer; Servier; Umoja
    Received grants for clinical research from: Autolus; Fate; Genentech; Servier; Takeda

  • Jessica Leonard, MD

    Assistant Professor of Medicine
    Division of Hematology/Medical Oncology
    Oregon Health and Science University
    Portland, Oregon

    Disclosures

    Jessica Leonard, MD, has no relevant financial relationships.

Editor

  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC

    Disclosures

    Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) (Universal Activity Number: JA0007105-0000-22-356-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Acute Leukemias

Authors: Courtney D. DiNardo, MD, MSCE; Harry P. Erba, MD, PhD; Naval G. Daver, MD; Elias J. Jabbour, MD; Aaron C. Logan, MD, PhD; Jae H. Park, MD; Jessica Leonard, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 10/19/2022

Valid for credit through: 10/19/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Intensive Frontline Therapy for AML

How are recent updates to the ELN genetic risk classifications affecting intensive frontline management of AML?
Harry P. Erba, MD, PhD

Lower-Intensity Frontline Therapy for AML

What’s the latest on doublet and triplet combinations for patients with AML who are ineligible for intensive chemotherapy?
Courtney D. DiNardo, MD, MSCE

Relapsed/Refractory AML

Which targeted therapies, immunotherapies, and emerging agents are showing the most promise in pretreated AML?
Naval G. Daver, MD

Philadelphia-Positive ALL

Could the high molecular response rates to the newest TKI regimens mean the end of transplant and chemotherapy in Ph-positive ALL?
Elias J. Jabbour, MD

Philadelphia-Negative ALL: Immunotherapy in the Frontline

How could moving novel immunotherapies to the frontline improve outcomes in Ph-negative ALL?
Aaron C. Logan, MD, PhD

Relapsed/Refractory ALL: Sequencing vs CAR T-Cell Therapy

What’s the future of relapsed/refractory ALL management: CAR T cells, immunotherapies, or both?
Jae H. Park, MD

Assessing Measurable Residual Disease in Acute Leukemias

How should we be using MRD to assess response and guide treatment decisions in AML and ALL?
Jessica Leonard, MD
 

Learning Feedback Questions

Please answer these questions to complement your learning experience.